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ABSTRACT
The increasing prevalence of carbapenem-resistant Acinetobacter baumannii (CRAB) strains in intensive care units has caused
major problems in public health worldwide. Our aim was to determine whether this phage could be used as an alternative thera-
peutic agent against multidrug-resistant bacterial strains, specifically CRAB clinical isolates, using a mouse model. Ten bacterio-
phages that caused lysis in CRAB strains, including blaOXA-66-like genes, were isolated. YMC13/01/C62 ABA BP (phage B-C62),
which showed the strongest lysis activity, was chosen for further study by transmission electronmicroscopy (TEM), host range
test, one-step growth and phage adsorption rate, thermal and pH stability, bacteriolytic activity test, genome sequencing and
bioinformatics analysis, and therapeutic effect of phage using a mouse intranasal infection model. The phage B-C62 displayed
high stability at various temperatures and pH values and strong cell lysis activity in vitro. The phage B-C62 genome has a dou-
ble-stranded linear DNA with a length of 44,844 bp, and known virulence genes were not identified in silico. In vivo study
showed that all mice treated with phage B-C62 survived after intranasal bacterial challenge. Bacterial clearance in the lung was
observed within 3 days after bacterial challenge, and histologic damage also improved significantly; moreover, no side effects
were observed.
IMPORTANCE
In our study, the novel A. baumannii phage B-C62 was characterized and evaluated in vitro, in silico, and in vivo. These re-
sults, including strong lytic activities and the improvement of survival rates, showed the therapeutic potential of the phage B-
C62 as an antimicrobial agent. This study reports the potential of a novel phage as a therapeutic candidate or nontoxic disinfec-
tant against CRAB clinical isolates in vitro and in vivo.
Bacteriophages (phages) are viruses that infect bacteria and areubiquitous in the biosphere (1). Recently, phages have been
reported as therapeutic agents to treat bacterial infectious diseases
in humans and animals (2–5). Phages possess several advantages
as therapeutic agents over conventional antibiotics, in that they
have precise effective bacteriolytic activity against target bacteria
and have shown no critical side effects to date (6–8).
Antimicrobials have been crucial for the prevention and treat-
ment of infectious diseases in humans, animals, and plants since
the 1940s (9). Today, however, certain isolated strains have exhib-
ited resistance to all currently available commercial antimicrobial
agents (9, 10). Many scientists and medical professionals have
emphasized the urgent need to prevent the emergence and spread
of drug-resistant bacteria (11). Despite efforts to reduce the dis-
semination of drug-resistant pathogens in health care settings,
antimicrobial resistance has been constantly increasing and be-
coming a serious global clinical challenge with little accompany-
ing novel antibiotic discovery (12). Hence, phages are currently
being viewed as alternative therapeutic agents (6).
Acinetobacter spp. are Gram-negative bacilli that are ubiqui-
tous and important infectious pathogens in clinical settings, and
they are responsible for various infections, including pneumonia,
meningitis, septicemia, wound infection, and urinary tract infec-
tion (13). In particular, A. baumannii is one of the major bacterial
species causing serious nosocomial infections in intensive care
units (ICUs). They exhibit a high rate of resistance to most com-
mercial drugs, leading to higher mortality and morbidity (14, 15).
Carbapenems are extended-spectrum -lactam antibiotics exhib-
iting potent and excellent efficacy, particularly in the treatment of
serious infections caused by multidrug-resistant Gram-negative
bacteria (16). However, the current emergence and prevalence of
A. baumannii expressing resistance to carbapenems have been in-
creasingly reported in many countries (17). These carbapenem-
resistant A. baumannii (CRAB) strains lead to community- and
hospital-acquired infections that are difficult to control and treat,
and these problems have caused a serious medical threat world-
wide (18, 19).
In this study, we isolated and characterized the lytic bacterio-
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phage B-C62, which is able to infect CRAB clinical isolates. Our
aim was to determine whether this phage could be used as an
alternative therapeutic agent against multidrug-resistant bacterial
strains, specifically CRAB strains, using a mouse model. This
study reports on the safety and therapeutic efficacy of a novel
phage against CRAB isolated from clinical samples, using the
mouse model as a surrogate host.
MATERIALS AND METHODS
Bacterial strains.A total of 45 clinical carbapenem-resistantAcinetobacter
species isolates were selected from clinical samples, including respiratory,
urine, and pus samples, at a university-affiliated hospital in 2013. The
identification and antimicrobial susceptibility of the clinical isolates
were determined using matrix-assisted laser desorption ionization–time
of flight mass spectrometry (MALDI-TOF MS; Vitek MS system; bio-
Mérieux Inc., Marcy l’Etoile, France) and the VITEKN132 system (bio-
Mérieux). Collected CRAB isolates were used for initial isolation and eval-
uation of the phage host spectrum. Clonal differences of the A. baumannii
isolates that showed clear zones on a plate, i.e., plaques, based on the
phage host spectrum test were confirmed using pulsed-field gel electro-
phoresis (PFGE) with the contour-clamped homogeneous electric field
(CHEF) DR-II system (Bio-Rad Laboratories, Hercules, CA). Phyloge-
netic analyses were performed using InfoQuest FP software (version 4.50;
Bio-Rad Laboratories, Inc.). To determine the epidemiological relation-
ships of these strains, multilocus sequence typing (MLST) was performed,
and results were analyzed using the MLST database (http://pubmlst.org
/abaumannii/). Detection of the OXA carbapenemase genes in A. bau-
mannii strains was performed by multiplex PCR (20). The modified
Hodge test (MHT) was performed for all isolates as previously described
by Lee et al. (21). The carbapenem-resistant YMC13/01/C62 strain was
specifically used as the host bacterial species for characterization and in
vivo testing in order to estimate the therapeutic potential of phage B-
C62.
Isolation and propagation of bacteriophage. Ten bacteriophages ca-
pable of lysing carbapenem-resistant Acinetobacter spp. were isolated
from sewage water at a hospital in South Korea. The isolation and purifi-
cation of phages were performed using polyethylene glycol (PEG; Sigma,
St. Louis, MO, USA) treatment and the double layer method (22). The
sewage sample was treated with NaCl (1 M; Merck) and PEG 8000 (final
concentration of 10%) and was incubated at 4°C for 24 h. The sample
solution was centrifuged and filtered using 0.22-m membranes (Milli-
pore Corporation, Bedford, MA, USA). Phages were harvested by ultra-
centrifugation (12,000  g for 1 h at 4°C) and resuspended in sterilized
sodium chloride-magnesium sulfate (SM) buffer (100 mM NaCl, 8 mM
MgSO4, 2% gelatin, 50 mM Tris-HCl, pH 7.5).
To amplify phages against collected clinical strains, phage samples (40
l) and all strains were mixed in 4 ml of Luria-Bertani (LB) broth medium
(Difco, Detroit, MI, USA) and incubated overnight at 37°C. The cultures
next were centrifuged (12,000  g for 10 min at 4°C) and filtered
(0.22-m membrane; Millipore Corporation, Bedford, MA, USA) to re-
move bacterial debris. The purification steps of single plaques using
plaque assays were repeated three times. Host bacterial strains (optical
density at 600 nm [OD600] of 0.5) in 4 ml of LB broth medium were mixed
with 10 l of purified phage solution and incubated at 37°C for 12 h with
shaking. Culture samples were centrifuged (12,000 g for 10 min at 4°C)
and filtered to remove cell debris. After PEG 8000 (a final concentration of
10%) treatment, the phage solutions were incubated for 12 h at 4°C and
centrifuged (12,000 g, at 4°C for 10 min), followed by resuspension in
SM buffer. The number of PFU of the concentrated phage solutions was
confirmed through plaque assays using the double layer method.
Transmission electron microscopy (TEM). Ten purified phage par-
ticles were mounted on copper grids and negatively stained with 2% ura-
nyl acetate for 15 s. Phage morphology was then observed using a trans-
mission electron microscope (JEM-1011; JEOL, Tokyo, Japan) at an
operating voltage of 80 kV.
Host range test. A total of 45 clinical carbapenem-resistant Acineto-
bacter species isolates were used for purified phage host range testing using
spot tests as described previously, with some modifications (23). Briefly,
the phage solution was spotted directly onto a bacterial lawn on the LB
agar plate and incubated at 37°C overnight. According to the degree of
clarity, the plaque-forming level of the phage was measured as a clear zone
() or turbid zone ().
Host cell lysis activity. A carbapenem-resistant A. baumannii
YMC13/01/C62 strain culture (early exponential phase; OD600 of 0.2) was
infected with the phage at a multiplicity of infection (MOI) of 0.1, 1, or 10
while shaking at 37°C. Samples were collected at 1-h intervals for 6 h, and
microbial growth was measured according to the OD600 using spectro-
photometry. This experiment was performed in triplicate.
Genome sequencing and bioinformatics analysis. The extraction of
phage genomic DNA was carried out using the phenol-chloroform pre-
cipitation method as described previously (24). The complete genome of
phage B-C62 was sequenced using a 454 GS Junior genome analyzer
(Roche, Branford, CT, USA). Gap filling was performed using standard
PCR. The entire genome sequence was determined using the Roche GS
Assembler, version 2.6 (Roche), and CLC Genomics Workbench 4.8
(CLCbio USA, Cambridge, MA). The NCBI open reading frame (ORF)
finder and GenMark.hmm software (25) were used for the prediction of
ORFs. The comparison of genome sequences with those of other phages
was performed using the NCBI (http://www.ncbi.nlm.nih.gov/) database,
MAUVE software (version 2.3.1) (26), and Easyfig software (version 2.1)
(27). BLASTP and PSI-BLAST searches (http://www.ebi.ac.uk/Tools/sss
/fasta/) were used to determine the similarity of all putative proteins in the
genome sequence. The tRNA genes were analyzed using the tRNAscan-SE
program (28).
Therapeutic effect of phage in themousemodel.To evaluate mortal-
ity due to phage B-C62, mice were divided into six groups: (i) phos-
phate-buffered saline (PBS) and SM buffer treated (n  6), (ii) A. bau-
mannii and SM buffer treated (n 6), (iii) PBS and phage B-C62 treated
(n 6), (iv) A. baumannii and phage B-C62 treated (MOI 10, n 6),
(v)A. baumannii and phage B-C62 treated (MOI 1; n 6), and (vi)A.
baumannii and phage B-C62 treated (MOI 0.1; n 6). Briefly, female
C57BL/6 mice, 7 to 8 weeks of age, first were immunized with 200 mg/kg
of body weight cyclophosphamide (Sigma, MO, USA) by intraperitoneal
(i.p.) injection, followed by a second i.p. injection after 48 h. Mice were
anesthetized with a Zoletil-Rompun mixture by i.p. injection (29). The
mice were inoculated with bacteriophage (1  1010 PFU/ml; 30 l)
through the same route after 30 min of intranasal bacterial (1  109
CFU/ml; 30 l) infection. Survival rate and body weight were monitored
for 12 days. For histological analysis, mice were divided into four groups:
(i) PBS and SM buffer treated (n 15), (ii) PBS and phage B-C62 treated
(n 15), (iii) A. baumannii and SM buffer treated (n 15), and (iv) A.
baumannii and phage B-C62 treated (MOI 10; n 15). Briefly, mice
(n  5 mice per group) were sacrificed at day 1, 3, or 5 after bacterial
infection, and lung tissues and serum samples were collected for analysis.
Lung tissues were homogenized and centrifuged at 8,000 rpm for 1 min.
The collected blood samples were centrifuged at 12,000 rpm for 20 min,
and the sera were collected. All of the samples were stored at80°C until
tested.
Histological analysis. The left lobe of one lung was removed from
each experimental group (n 5 mice per group) at day 1 or 3, fixed in 10%
formalin, and embedded in paraffin. Slides of hematoxylin-eosin (H&E)-
stained tissues were observed for histopathology analysis using an optical
microscope. Histopathology was evaluated for severity level in a blinded
manner. Lung tissue inflammation was evaluated as a severity score of
inflammation: 0, no inflammatory lesions; 1, mild; 2, mild to moderate; 3,
moderate; 4, moderate to severe; 5, severe.
Bacterial clearance and phage counting. The collected lung samples
were weighed and homogenized at each time point (day 1, 3, or 5) and
then serially diluted in PBS. Lung lysates and sera were plated on LB agar
plates containing ampicillin (50 g/ml) to determine viable bacterial
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counts. Bacteriophage counts in lung lysates and sera were determined
using the double layer agar method.
Ethics statement. All animal studies were approved by and followed
the guidelines and regulations of the Institutional Animal Care and Use
Committee, Yonsei University College of Medicine, Seoul, South Korea.
Statistical analysis. Statistical calculations for survival rate were per-
formed using the log-rank (Mantel-Cox) test, and comparisons of bacte-
ria, phage count, and cytokine levels were performed using a one-way
analysis of variance (ANOVA) with Tukey’s multiple-comparison test
(GraphPad Prism software, version 6; GraphPad Software, San Diego, CA,
USA).
Nucleotide sequence accession number. The complete genomic se-
quence of phage B-C62 was deposited in the GenBank database under
accession number KJ817802.
RESULTS
Characterization of bacteria. All 45 clinical A. baumannii strains
used in this study were multidrug-resistant A. baumannii strains
resistant to carbapenems (Table 1; also see Table S1 in the supple-
mental material). Sixteen of 45 CRAB strains, which showed a
clear zone by phage B-C62 in the spot test, were clonally different
when reviewed by PFGE (see Fig. S1). Based on multiplex PCR, 16
CRAB isolates contained the blaoxa-66-like genes encoding the class
D carbapenem-hydrolyzing oxacillinases, and these strains
showed positive results on the Hodge test. These isolates also were
identified as sequence type 357, belonging to European clone II
based on MLST analysis (Table 1).
Of the 16 isolates, oneA. baumanniiYMC13/01/C62 strain was
used as the host for phage B-C62. This strain was resistant to
amikacin, ceftazidime, cefepime, cefotaxime, gentamicin, imi-
penem, levofloxacin, meropenem, piperacillin-tazobactam, and
co-trimoxazole but was susceptible to colistin, minocycline, and
tigecycline and was intermediate to ampicillin-sulbactam.
Phage characterization. Ten Acinetobacter phages, including
phage B-C62, were isolated in this study. All of the phages be-
longed to the Myoviridae family and the order Caudovirales (see
Fig. 6; see also Fig. S2 in the supplemental material). As shown in
Table 1, the infection rate of phage B-C62 was approximately
FIG 1 Bacteriolytic effect of phage B-C62 against carbapenem-resistant A.
baumannii YMC13/01/C62. Early-exponential-phase cultures (OD600 of 0.2)
of A. baumannii YMC13/01/C62 were infected by phage B-C62 at an MOI of
0.1, 1, or 10 and cultured for up to 6 h. The results shown are the means 	
standard deviations from triplicate experiments.
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35% (16 of 45) against CRAB clinical isolates based on spot test
analyses. Moreover, phage B-C62 formed plaques on two colis-
tin-resistant A. baumannii strains. However, no other tested
Gram-negative bacterial strains were lysed by phage B-C62, in-
cluding Pseudomonas aeruginosa and Escherichia coli strains (data
not shown).
According to the one-step growth curve analysis, phage B-
C62 showed a latency period of approximately 20 min with a burst
size of 76 PFU/cell (see Fig. S3a in the supplemental material) and
an absorption rate of approximately 80% within 1 min (see Fig.
S3b). Phage B-C62 showed high temperature stability at 25°C
(99%) and 37°C (97%) for up to 9 h and maintained activity at
62%, 55%, and 46% at 40°C, 50°C, and 60°C, respectively. No
activity was detected at 70°C (see Fig. S4a). The optimal pH for
phage B-C62 was at pH 7 (91%) and pH 7.5 (92%) for up to 10
months. High stability (
90%) was retained at pH 4 to pH 10 at
day 1, with significant stability (
60%) noted over 10 months (see
Fig. S4b).
The lysis activity of phage B-C62 against A. baumannii
YMC13/01/C62 was evaluated in cultured bacteria in the early
exponential phase with phage at MOIs of 0.1, 1, and 10. Phage
inhibited bacterial growth at all MOIs (OD600 of 0.3 at 6 h),
while the bacterial culture without phage grew rapidly (OD600 of
1.3 at 6 h) according to culture time points (Fig. 1).
Genome sequencing and bioinformatics analysis. The com-
plete genome sequence of phage B-C62 was determined to con-
tain 44,844 bp, with read lengths of 90,862 and coverage of 937
with a GC content of 37.6%. Among the 84 ORFs identified, 71
were predicted on the negative strands while only 13 ORFs were
predicted on the positive strand. Of the 84 ORFs, 75 had a pre-
dicted ATG initiation codon, 8 were predicted to contain GTG,
and 1 was posited to harbor TTG. Only 21 (25%) of the 84 ORFs in
the genome were assigned putative functions by BLASTP and PSI-
BLAST, and no predicted tRNAs were found in the genome (see
Table S2 in the supplemental material). Compared with other
phage genomes, the phage B-C62 genome showed highest sim-
FIG 2 Genome comparison of A. baumannii phage B-C62, A. baumannii phage IME-AB2, phage AB1, and phage AP22 at the DNA level. This analysis was
carried out using MAUVE software 2.3.1 with the default parameters. The connecting lines indicate similar regions between B-C62 ORFs and the three
Acinetobacter phages. (A) White blocks indicate annotated genes with the reverse strand shifted downward. (B) The genome map of B-C62 and its comparison
with ORFs from phage IME-AB2 as determined by Easyfig software, which indicates a putative function of each ORF, with the direction of transcription shown
by arrows.
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ilarity of 80%, 57%, and 50% with phage IME-AB2 (GenBank
accession number JX976549), phage AB1 (GenBank accession
number HM368260), and phage AP22 (GenBank accession num-
ber HE806280), respectively (Fig. 2A). Nucleotide alignment of
the four A. baumannii phages showed that some functional re-
gions were highly homologous, with significant rearrangements
observed. In the genome map of phage B-C62, each of the anno-
tated genes was divided into three groups: (i) phage head mor-
phology and structure (orf45, orf46, orf48, orf51, orf55, orf61, orf65,
orf68, orf69, orf80, orf82, and orf83), (ii) phage DNA replication
and modification (orf22, orf23, orf30, orf34, orf40, and orf63), and
(iii) lysis (orf42) (Fig. 2B; also see Fig. S5 and Table S2).
Effect of phage treatment against bacterial infection in the
mouse model. To evaluate the therapeutic effects of B-C62
against bacterial infection and the safety of B-C62 in the mouse
model, we evaluated the survival rate, histological features of the
lung, the number of bacteria and bacteriophage in the lung, and
immunogenicity through intranasal administration of phage
against a carbapenem-resistant Acinetobacter sp. strain. The min-
imum lethal dose (MLD) against bacterial infection through the
intranasal route was confirmed as 2 109 CFU per mouse prior to
the experimentation (data not shown). As shown in Fig. 5A, after
the injection of cyclophosphamide (CP), the intranasal bacteri-
um-infected mouse group without phage administration died by
day 3 postinfection, and all mortality was noted within day 7
postinfection. After bacterial infection, phage-treated mouse
groups exhibited a 100% survival rate at an MOI of 10, and at
MOIs of 1 and 0.1 the mice showed survival rates of 50% and
16%, respectively. Therefore, survival rates differed according
to phage MOI, and only mice that were phage treated had reduced
or nonexistent mortality or morbidity (Fig. 3).
Histological changes and cytokine analysis. To assess the
therapeutic effect of phage in intranasally bacterium-infected
mice, the histological changes of lung samples were observed us-
ing H&E staining. The bacterium-infected group showed severe
thickening of the alveolar walls and an infiltration of neutrophils
in the alveolar space at days 1 and 3 (Fig. 4A, c and k). In contrast,
most histological sections of the phage-treated group after bacte-
rial infection exhibited moderate alveolar wall thickening and
neutrophils in the alveolar space at day 1. The sections of lung at
day 3 showed mild to moderate alveolar wall thickening and a
number of neutrophils in the alveolar space (Fig. 4A, d and l). The
buffer-treated control group showed slightly increased neutrophil
numbers in response to PBS and SM buffer treatment at day 1 (Fig.
4A, a and i); however, no histological changes were seen in the
lung (Fig. 4A, e and m). Moreover, the phage-administered group
revealed little damage in the lung compared to the control group
(Fig. 4A, b and j), with no difference identified on day 3 (Fig. 4A,
f and n).
To evaluate the immunogenicity of phage administration and
bacterial infection in the lung, we measured the concentrations of
cytokines (tumor necrosis factor alpha [TNF-] and interleukin-6
[IL-6]) in the lungs and blood of five mice from each mouse group
at day 1 or 3 after bacterial infection or phage administration (see
the supplemental material). The level of TNF- in the lungs of the
phage-treated postinfection group was slightly reduced relative to
FIG 3 Survival kinetics (A) and body weights (B) of phage B-C62-administered mice infected with A. baumannii YMC13/01/C62. (A) Female C57BL/6 mice
were intranasally inoculated with phage and/or bacteria.●, buffer treated (PBS and SM); , bacterium infected;Œ, treated with phage only; Œ, bacterium infected
and phage treated 30 min postinfection (MOI 10);, bacterium infected and phage treated 30 min postinfection (MOI 1);o, bacterium infected and phage
treated 30 min postinfection (MOI 0.1). (B) Body weights of C57BL/6 mice were measured daily. The black arrow represents a second cyclophosphamide (CP)
administration and the first bacterial infection time point. Values given are averages (n 6 mice per group). Statistical analysis was performed using the log-rank
(Mantel-Cox) test. ***, P 0.0001; *, P 0.0236.
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that in the bacterium-infected group at day 1; however, the differ-
ence was not statistically significant (see Fig. S6a in the supple-
mental material). On the other hand, a significant reduction in
IL-6 was seen in the bacterium-infected group (****, P 0.0001;
see Fig. S6b). The levels of TNF- and IL-6 in the phage-treated
group were similar to those of the control group. Levels of TNF-
and IL-6 were not detected in serum collected at day 1 or day 3
from any experimental group (data not shown). Also, the quanti-
FIG 4 Histopathological changes in mouse lungs of bacterium (A. baumannii YMC13/01/C62)-infected mice or phage B-C62-treated mice according to H&E
staining (magnification with a 10 objective [a to d and i to l] and a 40 objective [e to h and m to p]) (A) and histological severity of mouse lungs (B). We tested
a control (PBS and SM buffer) group, phage B-C62-treated group, A. baumannii-infected group, and phage B-C62-treated group (30 min postinfection) on
day1 (a to h) and day 3 (i to p). One-way ANOVA with Tukey’s multiple-comparison test was used to compare histological severity (****, P 0.0001; **, P 0.05).
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fication of the histologic severity of infection in lung tissues
showed a significant reduction in the phage-treated group postin-
fection (day 1, score of 3.6; day 3, score of 2.1) relative to the
bacterium-infected group (day 1, score of 4.8; day 3, score of 4.5).
The phage-administered group (day 1, score of 1; day 3, score of 0)
presented a mild or zero severity score (Fig. 4B).
Bacterial and phage counts in the mouse lungs of each group
were measured at days 1, 3, and 5. Bacteria counts in the phage-
treated group were reduced from 8.6 log10 to 6.4 log10 compared
with those of the bacterium-infected group at day 1, and most of
the bacteria were eliminated from the lungs at day 3. Bacteria were
not detected in the buffer-treated group or phage-administered
group at any of the time points (Fig. 5A). The PFU value of the
phage-treated postinfection group (10.8 log10) was increased by
more than 1 log unit relative to that of the phage-treated group
(9.1 log10) at day 1, which was maintained until day 3. At day 5, the
phage count sharply decreased from 10.8 log10 to 3.4 log10 in the
phage-treated group postinfection and 9.1 log10 to 1.5 log10 in
the phage-administered group (Fig. 5B). Phage was not detected
in the buffer-treated group or in the bacterium-infected group at
any time point (data not shown). These results indicate that phage
B-C62 has significant therapeutic potential against CRAB.
DISCUSSION
In recent decades, the rise of multidrug-resistant pathogens and
the decrease of newly approved antibiotics have led to the use of
bacteriophages as a novel alternative strategy for control of anti-
biotic-resistant bacteria (30, 31). Lately, some phage products,
such as ListShield and ListexP100, have been approved by the U.S.
Food and Drug Administration (USFDA) for use as food bio-
preservatives (32).
Most phages tend to have high host specificity and a narrow
host range, leading to the rapid emergence of phage-resistant bac-
teria on lytic phages. This resistance is a major obstacle to phage
applications as therapeutic agents (6). However, the combination
of phages and antibiotics has been researched as a successful strat-
egy to deal with the above-described drawbacks (32). Therefore,
the isolation and characterization of many novel and strong lytic
phages are very important for their application in phage therapy
for treatment of multidrug-resistant pathogens.
Colistin, as last-resort therapy, is the most effective agent for
treatment of several infectious diseases caused by multidrug-resis-
tant (MDR) Gram-negative pathogens, including CRAB strains
(33). However, it has a risk of renal toxicity. Moreover, the emer-
gence of colistin-resistant A. baumannii in a clinical setting has
been reported recently (33, 34). In spite of several global incidents
with MDR A. baumannii, the isolation and detailed characteriza-
tion of lytic phages against CRAB strains have been rarely reported
(35).
To date, approximately 20 A. baumannii phages have been iso-
lated from sewage, the hospital environment, and marine sedi-
ment samples (35). Based on morphology as determined by TEM,
these phages were classified as members of the Myoviridae, Sipho-
viridae, and Podoviridae families of the Caudovirales order (35).
To date, most of these phages have been characterized for phage
stability, antibacterial activity, or genome sequence and have been
suggested as therapeutic applications against MDR A. baumannii
(23, 35–41). In this study, we isolated and characterized the
lytic phage B-C62, which is specific to clinical A. baumannii
isolates, and evaluated its potential as an alternative therapeutic
agent against CRAB isolated from patients using the mouse
lung infection model. Although Soothill (42) demonstrated
that phage BS46 effectively protected mice against highly viru-
lent A. baumannii peritoneal cavity injection, the efficacy of
phages for the therapeutic treatment of infectious diseases
caused by MDR A. baumannii resistant to carbapenems, includ-
ing imipenem and meropenem, has not been studied using an
animal lung infection model.
In this study, 16 of 45 CRAB clinical strains, which were
strains susceptible to the phage B-C62, were found to contain
a blaOXA-66-like gene that is one of the known carbapenemase genes
reducing susceptibility to carbapenems (43). It is worth noting
that all of these isolates were the ST357 A. baumannii strains that
FIG 5 Bacterial CFU (A) and phage PFU (B) in the lungs of phage B-C62-
treated and untreated mice after bacterial infection (A. baumannii YMC13/01/
C62). Phage were administered 30 min postinfection. Five mice were sacrificed
from each mouse group at days 1, 3, and 5. The horizontal bar indicates the
mean value for each group. The counts were compared using one-way
ANOVA with Tukey’s multiple-comparison test (****, P  0.0001; **, P 
0.05).
Jeon et al.
4206 aem.asm.org July 2016 Volume 82 Number 14Applied and Environmental Microbiology
were first isolated and reported in South Korea in 2013 (Table 1)
(44). Also, the 16S rRNA methylase gene armA (45), which is one
of the aminoglycoside resistance genes, was detected in 10 CRAB
strains (YMC13/01/R317, R280, R224, R1400, R1224, R1919,
R2058, R1049, R3197, and B720) (data not shown).
The phage B-C62 belongs to the Myoviridae family, which is
composed of an 62-nm-diameter head and a contractile tail
89 nm in length (n 10) (Fig. 6) and is similar in morphology to
A. baumannii phage AP22 (41). The phage B-C62 showed a rel-
atively longer latency period and a smaller burst size than most
known Acinetobacter phages belonging to Myoviridae (40, 46).
Phage B-C62 exhibited significant host cell lytic activities against
the host bacterial strain at all MOIs (Fig. 1). In addition, phage
B-C62 maintained significant antibacterial activity and stability
at various pH and temperature levels compared to other Acineto-
bacter phages, such as phage AB1 and phage ZZ1, belonging to the
Myoviridae (see Fig. S4 in the supplemental material) (46, 47).
Among the known A. baumannii phages, phage B-C62 has sub-
stantial similarity in genome sequence, genome size, and GC con-
tent to phage IME-AB2 and phage AP22, which also belong to the
Myoviridae family of tailed phages (Fig. 2). The phage B-C62
genome did not possess known virulence genes such as toxin-
related or antibiotic resistance-related genes. These results suggest
that B-C62 is a lytic phage that is specific to A. baumannii and
could be used to effectively eliminate CRAB strains from clinical
environments.
In this research, we observed that a single dose of phage B-
C62 at an MOI of 10 showed effective therapeutic potential in the
mouse model. This phage increased the survival rate of mice with
CRAB infections. Moreover, a complete clearance of CRAB
YMC13/01/C62 from the lung was observed in all surviving mice
at day 3. Also, phage B-C62 was not harmful to the mice at the
highest-titer phage injections, and histological results corre-
sponded with the above-described findings. These studies demon-
strate that the A. baumannii phage B-C62 can be used to treat
mice with intranasal CRAB infection; therefore, phage B-C62 is
a viable candidate for phage therapy against CRAB infections. Our
results also support that bacteriophages can be an effective alter-
native strategy to conventional antibiotic treatment for therapy
against MDR pathogens.
In this study, the novel Acinetobacter phage B-C62, which lyses
OXA-66-like carbapenemase-producing A. baumannii strains, was
characterized in vitro and in silico and was evaluated in vivo for its
therapeutic potential to treat lung infection. The current results de-
scribe fundamental research into bacteriophage therapy for lung in-
fection in the mouse model.
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